Immunologic characterization of platelet-rich plasma (PRP) to identify biomarkers as predictors of response when used in osteoarthrosis patients

Recruiting

Conditions: M16.0
M16.2
M16.3
M16.4
M16.5
M16.6
M16.7
M16.9
M17.0
M17.1

Registration Number: DRKS00026175

Lead Sponsor: Charité - Universitätsmedizin BerlinCentrum für Muskuloskeletale ChirurgieCampus Charité Mitte

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

Volljährige Patient*innen jeden Geschlechts,
Symptomatische Gonarthrose des Hauptbelastungsbeins (Arthrosegrad I - III nach Kellgren-Lawrence bzw. OARSI-Joint Space Narrowing Score I - II),
Symptomatische Coxarthrose (Arthrosegrad I - II nach Kellgren-Lawrence),
Symptomatische Omarthrose (Arthrosegrad I - II nach Kellgren-Lawrence),
Symptomatische Tendinopathien (Achillessehne, Bicepssehne, Patellasehne)

age > 17 years, osteoarthritis of the knee (Kellgren-Lawrence I - II), osteoarthritis of the hip (Kellgren-Lawrence I - II), osteoarthritis of the shoulder (Kellgren-Lawrence I - II), symptomatic tendinopathy (achilles tendon, biceps tendon, patellar tendon)

Exclusion Criteria

General exclusion criteria: no consent in study participation, inflammatory/rheumatic disease; exclusion criteria for osteoarthritis patients: major trauma or surgery at the affected joint within the past 12 months, arthroscopy of the affected joint within the past 12 months, previous procedure at the cartilage of the affected joint within the past 12 months, previous injection therapy within the past 12 months; exclusion criteria for tendinopathy patients: surgery at the affected tendon within the past 12 months, previous injection therapy within the past 12 months

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between KOOS at 6 months follow-up and patients' individual cellular and molecular PRP composition <br>

Secondary Outcome Measures

Name	Time	Method
- individual cellular PRP composition (u. a. CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CD57, CD197 (CCR7), CD279 (PD-1), FoxP3 und Helios)<br>- individual molecular PRP composition (u. a. TNF-a, G-CSF, IFN-?, IL-6, IL-10)<br>- change of symptoms following PRP application (measured through KOOS, numeric rating scale, and analgesics used) <br>- change of gait following PRP application (measured through 3D gait analysis) <br>- change of Patient Reported Outcome Measures following PRP therapy: Promis-29, WORC Index, WOSI, DASH, SSV, DART shoulder, FFI, FAAM, FADI, ATRS, Tegner Score, OMAS, FADI, PRTEE, MEPS, SEV, SKV, KOOS, IKDC, DART knee, Lysholm-Score, DART hip, WOMAC, SHV, HOOS<br>